Are Patients to Blame for These Shortages? A Clear-Eyed Look at the GLP-1 Supply Crisis

Why This Debate Erupted in the First Place

The conversation about patient blame did not come out of nowhere. When Ozempic, Wegovy, Mounjaro, and Zepbound became household names between 2021 and 2023, pharmacies began reporting empty shelves. Primary care offices, endocrinologists, and weight-management programs like Calibrate all fielded panicked calls from patients who could not fill prescriptions.

Media coverage followed a predictable arc: social media "Ozempic influencers" were spotlighted, celebrities admitted to off-label use, and the phrase "vanity drug" appeared in major publications. The implicit message was that people using these medications for weight loss had stolen supply from people with diabetes who needed them to survive.

That framing felt emotionally coherent. It was also incomplete.

What the FDA Actually Said

The FDA added injectable semaglutide to its drug shortage database in August 2022. The agency's official shortage page listed the cause as "demand increase" for all affected formulations. The FDA does not have a category on its shortage form for "patient misuse." Demand increase is a supply-demand mismatch, not a moral failing.

Tirzepatide (Mounjaro, Zepbound) entered the shortage list in December 2022, per FDA records, again citing demand.

The Scale of Untreated Obesity

The CDC estimates that 41.9% of U.S. Adults had obesity as of 2017-2020, representing roughly 100 million people. Wegovy received FDA approval for chronic weight management in June 2021. Before that approval, no GLP-1 receptor agonist had ever been marketed specifically for obesity in the United States. Novo Nordisk and Eli Lilly were not manufacturing at the scale that 100 million potential patients would require. No manufacturer on earth was.

Demand was not manufactured by irresponsible patients. It was the predictable outcome of approving the most effective anti-obesity medications in clinical history for a population that had been waiting decades for meaningful options.

The Real Causes of the Shortage: A Supply-Chain Breakdown

Blaming patients sidesteps a more complicated structural story. The shortage had at least four distinct drivers, none of which were controlled by individual prescription holders.

Manufacturing Constraints on Active Pharmaceutical Ingredients

Semaglutide is a 31-amino-acid GLP-1 analogue with a fatty-acid side chain that enables once-weekly dosing. Producing it requires specialized solid-phase peptide synthesis equipment that takes years and hundreds of millions of dollars to build and validate. Novo Nordisk's existing fill-finish lines in Denmark and the United States were sized for the diabetes market. Adding obesity to the label overnight multiplied demand in a way no manufacturer could instantly absorb.

Novo Nordisk publicly committed more than $6 billion to expanding production capacity across sites in Denmark, France, and Clayton, North Carolina. Capacity expansions of this kind typically require 18 to 36 months from ground-breaking to commercial output. There is no shortcut in pharmaceutical manufacturing when sterile injectable peptides are involved.

The Auto-injector Device Problem

The drug itself is only part of the product. Both Ozempic and Wegovy are delivered in proprietary auto-injectors that require their own supply chains for polypropylene, stainless steel needles, and electronic safety mechanisms. A shortage of device components, separate from the drug shortage, compounded the problem in 2022 and 2023. Patients and prescribers had no visibility into this layer of the supply chain at all.

FDA Regulatory Requirements at Approval

When the FDA approved Wegovy in June 2021, it required risk evaluation and mitigation strategies (REMS) that include specific dispensing controls. Those controls take time for pharmacy networks to implement. Specialty pharmacy distribution channels were not ready for the volume Wegovy generated within its first six months on the market.

Off-Label Prescribing of Ozempic for Weight Loss

This is the one driver where prescribers, not patients, made choices that influenced supply. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Before Wegovy became available in sufficient supply, many physicians prescribed Ozempic off-label for weight management. That off-label use drew from the same inventory that diabetes patients relied on.

The decision to prescribe off-label belongs to physicians, not patients. Patients receiving a prescription in good faith from a licensed clinician bear no meaningful responsibility for the systemic effects of that off-label prescribing pattern on the broader supply.

What the Clinical Evidence Says About Who Needs These Drugs

The clinical case for GLP-1 receptor agonists in obesity is not marginal. It is among the strongest bodies of evidence in modern metabolic medicine.

STEP-1: Semaglutide 2.4 mg for Obesity

In STEP-1 (N=1,961), published in the New England Journal of Medicine in 2021, participants receiving semaglutide 2.4 mg subcutaneously once weekly achieved a mean body-weight reduction of 14.9% at 68 weeks, compared with 2.4% for placebo (P<0.001). More than 86% of semaglutide participants lost at least 5% of body weight.

The trial enrolled adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity. That is not a population of people seeking cosmetic weight loss. It is a population with medically significant obesity.

SURMOUNT-1: Tirzepatide for Obesity

In SURMOUNT-1 (N=2,539), published in the New England Journal of Medicine in 2022, participants receiving tirzepatide 15 mg once weekly lost a mean of 20.9% of body weight at 72 weeks, versus 3.1% for placebo (P<0.001). These reductions approach or exceed outcomes typically seen with bariatric surgery.

SELECT: Cardiovascular Outcomes

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, with no history of diabetes. This was not a weight-loss trial. It was a cardiovascular outcomes trial, and it enrolled patients who would almost universally be considered medically appropriate candidates.

The patient population demanding these drugs is sick. Framing that population as irresponsible consumers who caused their own shortage is not supported by the enrollment criteria of the trials that generated demand.

How Telehealth Programs Like Calibrate Fit Into This Picture

Calibrate launched in 2021 as a metabolic health program combining GLP-1 prescriptions with one year of structured coaching covering food, sleep, exercise, and emotional health. Its model was built on the same clinical evidence base described above.

Critics pointed to programs like Calibrate as drivers of off-label and non-specialist prescribing that aggravated shortages. That criticism deserves honest examination, not reflexive dismissal.

What Calibrate and Similar Programs Actually Do

Calibrate's clinicians are licensed prescribers in each state where the program operates. Prescriptions go through licensed U.S. Pharmacies. The program uses the same FDA-approved agents, at the same doses, for the same indicated population, as a hospital-based obesity medicine program would. The difference is access and delivery model.

If telehealth programs are blamed for shortages, the implicit argument is that patients without access to academic medical centers or obesity medicine specialists should not receive these medications. That is a coverage and equity argument dressed as a safety argument.

The Compounded Semaglutide Question

During the shortage period, compounding pharmacies began producing semaglutide formulations using semaglutide sodium or semaglutide acetate salts, which are different chemical entities from the base used in Ozempic and Wegovy. The FDA issued a safety communication in May 2023 warning that compounded semaglutide products had not been reviewed for safety, effectiveness, or quality.

Compounding is legal under specific statutory conditions. When a drug is on the FDA shortage list, Section 503A and 503B pharmacies may compound it. When a drug comes off the shortage list, that legal pathway narrows significantly. The FDA has been explicit that compounding pharmacies may not produce copies of commercially available FDA-approved drugs once the shortage resolves.

Patients who used compounded semaglutide during the shortage period were generally acting on clinician recommendations, not making independent pharmaceutical decisions. Blaming those patients for the shortage, or for the regulatory complexity of compounding, conflates downstream behavior with upstream policy failures.

What the Endocrine Society and Obesity Medicine Guidelines Say

The Endocrine Society's 2023 clinical practice guidelines on obesity pharmacotherapy, available via the Journal of Clinical Endocrinology and Metabolism, recommend GLP-1 receptor agonists as first-line agents for adults with a BMI of 30 or higher, or 27 or higher with comorbidities. The guidelines do not restrict these recommendations to patients seen in specialty settings.

The Obesity Medicine Association similarly endorses access to FDA-approved anti-obesity medications through primary care and telehealth channels, noting that only about 3% of eligible patients have historically received pharmacotherapy for obesity, a treatment gap the guidelines describe as a "public health failure."

A practical framework for thinking about appropriate GLP-1 access looks like this:

HealthRX Triage Framework: Is a GLP-1 Prescription Medically Appropriate?

1. BMI criteria met (30 or higher, or 27 or higher with a documented comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
2. Prescriber is licensed in the patient's state.
3. Prescription issued through an FDA-registered pharmacy.
4. No contraindications present (personal or family history of medullary thyroid carcinoma, MEN2, or known hypersensitivity).
5. Ongoing clinical follow-up is available.

If all five criteria are met, the prescription is clinically appropriate regardless of whether it came from an academic endocrinologist or a telehealth platform. The channel does not determine appropriateness. The clinical criteria do.

As Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital and Harvard Medical School, has stated in the literature: "Obesity is a disease, not a lifestyle choice, and we need to treat it with the same rigor we bring to hypertension or hyperlipidemia."

Who Bears Actual Responsibility for the Shortage?

Responsibility for the shortage sits at several institutional levels, none of which is the individual patient.

Manufacturers

Novo Nordisk and Eli Lilly had years of clinical-trial data showing the efficacy and likely commercial success of these agents. Scale-up planning should have begun earlier. Both companies have acknowledged capacity shortfalls and committed substantial capital to remediation, but the timing of those investments did not match the timing of FDA approval.

Regulators

The FDA approved Wegovy in June 2021 without requiring Novo Nordisk to demonstrate adequate supply before launch. Post-market supply adequacy is not currently part of the FDA's approval criteria. That is a policy gap, not a patient behavior problem.

Payers

Medicare Part D was prohibited from covering anti-obesity medications until the Treat and Reduce Obesity Act gained traction. Most commercial payers excluded GLP-1 agents for obesity through 2022 and 2023, pushing patients toward cash-pay options, including telehealth programs and compounding pharmacies. Payer restrictions did not cause the shortage, but they shaped who accessed the drugs and through which channels.

Prescribers

Physicians who prescribed Ozempic off-label for weight loss before Wegovy was reliably available made a medically reasonable choice for their patients. That choice had aggregate effects on supply that individual prescribers could not foresee or control.

The Equity Dimension Nobody Discusses Enough

The "patients are to blame" narrative tends to focus on affluent patients paying cash for GLP-1 medications. It rarely acknowledges that the patients most harmed by the shortage were lower-income patients with type 2 diabetes on fixed incomes who could not substitute a different medication or pay out of pocket for an alternative.

Formulary restrictions, prior-authorization requirements, and cost-sharing structures mean that GLP-1 access has never been equitably distributed. A supply shortage layered onto an inequitable access system predictably harms the most vulnerable patients first. That is a failure of payer policy and distribution infrastructure, not of patient demand.

CDC data show that obesity prevalence is highest among Black and Hispanic adults, the same populations that face the greatest barriers to specialty care, the highest rates of insurance underinsurance, and the most limited access to telehealth services with integrated clinical support.

What Patients and Prescribers Should Do Right Now

The FDA removed semaglutide injectable from its active shortage list for most formulations by late 2024, though local pharmacy availability continues to vary. Tirzepatide similarly came off the list for most dosage forms. Patients currently on these medications or seeking to start should take the following steps.

Check whether your specific dose and formulation is available at your pharmacy before assuming a shortage still applies. Shortages are product-specific and dose-specific. The 0.5 mg Ozempic pen may be available when the 2 mg pen is not.

Ask your prescriber about therapeutic alternatives if your formulation remains unavailable. Dulaglutide (Trulicity) and liraglutide (Victoza, Saxenda) are approved GLP-1 agents that remained more consistently available during the semaglutide shortage period, though with lower efficacy data.

Do not source medication from unverified online pharmacies or unregistered compounders. The FDA's safety communication from 2023 documented cases of dosing errors and adverse events associated with compounded semaglutide products, as detailed here.

If you are a Calibrate member or a patient of any telehealth GLP-1 program, contact your program's clinical team before making any medication substitutions. Dose titration schedules and formulation equivalencies are not interchangeable without clinical guidance.

The SELECT trial established that semaglutide 2.4 mg reduces cardiovascular events by 20% in the appropriate population. Discontinuing therapy because of supply anxiety or guilt about "causing" a shortage is not a medically sound decision when the drug is available.